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In summary, for the use of local VF intervals as an imirx o; locai 
refractory periods, a sharp distinction must he made between iioi nml 
and ischemic myocardium. To our knowledge, a relation be (ween 
these parameters has not been established in ischemic myocardium. 
This is not surprising, because even assessment of refractory periods 
at one site at a time during ongoing ischemia is a cumbersome task 
because of the changing diastolic threshold of excitability. Finally, it 
may not be assumed that ischemia develops similarly in normal beat­
ing and fibrillating hearts.
Tobias Opthof, PhD 
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Regional Hyperinsulinemia Does Not Modulate 
/¿-Adrenergic Vasodilator Action
To the Editor:
With regard to the recent interesting and well-written article by 
Lembo et al1 concerning the effect of insulin on the ¿9-adrenergic 
vasodilator pathway, we would like to raise the following points: The 
authors conclude that insulin augments the /3-adrenergic vasodilator 
response in the human forearm, This conclusion is mainly based on 
the observation that the response to intra-arterial infusions of isopro­
terenol was potentiated by concomitant intra-arterial insulin infusion.
We feel that there may be a plausible alternative explanation for 
this main finding: Numerous groups have reported that insulin in 
itself, also when infused locally into the brachial or femoral artery, 
will induce a gradual increase in skeletal muscle blood flow.2'7 The 
combination of a gradual, slow-onset vasodilation of insulin itself 
together with an unaltered response to isoproterenol may well explain 
the observations reported by Lembo and associates. This combined 
effect may mimic a potentiating effect of insulin on isoproterenol- 
mediated vasodilation but in fact simply may be the sum of two 
independent vasodilator effects.
Although Lembo and associates claimed that 30 minutes of insulin 
infusion did not change blood flow, this does not exclude the possi­
bility that vasodilation would occur later on, as the effect is slow in 
onset and continuous.3'5 Furthermore, there does exist an important 
interindividual variability, most probably related to the forearm mus­
cle content.8 As the subjects in the study of Lembo had a relatively 
high mean body mass index (BMI) of just under 25 kg*m"2, some 
may actually have been slightly obese and could hence show a de­
creased or attenuated insulin-induced vasodilator effect, stressing 
even more the need for prolonged evaluation of effects of insulin 
alone. Furthermore, the chance that the vasodilator effect of insulin 
may be initially missed as the result of a type 1 error may be very 
high, since the different study groups were small. This also may ex­
plain why the differences were not found in response to infusion of 
sodium nitroprusside before and during insulin. Unfortunately, re­
sults of pooled data of insulin on blood flow are not given. Looking 
in more detail at Fig 2 of the article, it seems that after insulin itself 
(B2), a slight vasodilation already had occurred (according to Table 
I, forearm blood flow [FBF] from 3.0±0.5 to 3.2±0.5). It must be 
emphasized that the absolute change in FBF is correlated to the base­
line FBF, which means that a change in baseline would necessitate 
expression of the results in percentages above true baseline.9 The 
results of the experiments with isoproterenol in the study of Lembo
et al would therefore better be expressed as percentage change from
i
the second baseline,9
We have performed similar experiments and confirmed the local va- 
sodilatory effect of insulin in a large group of healthy subjects: After 30 
minutes of intra-arterial infusion of insulin (leading to exactly compa­
rable forearm venous insulin concentrations: 498±48 pmol'L“1), FBF 
increased from 2.2±0.3 to 2v8±0,4 mL• dL~1 • min~1 (n=27, P=,002). 
Mean percentage increase in blood flow was 38±11% (P=.001), but the 
variability was wide and ranged from —23% to +158%.
Furthermore, in experiments in which six dosages of isoproter­
enol (0.03, 0 .1,0.3,1.0, 3.0, and 10 ng-dL " 1 * min- ’) were infused 
into the brachial artery, before and after 60 minutes of concomi­
tant insulin infusion, exactly identical vasodilator responses to 
isoproterenol were observed . 10 Percentage increases in FBF 
after the six respective doses were 4.0±4.0% , 34.S± 12.6%, 
74.7±19.2%, 18l.8±35.1% , 316.4+51.6%, and 498.1±95.5% 
before and 5.6±5.9%, 44.4±19.0% , 67.1±17.1%, 156.0±37.3%, 
301,0±56.4%, and 492.8±  161.3% during insulin infusion (12 
healthy subjects; age, 22.3±2.1 years; BMI, 22.5±1.4 kg^nT2; 
P=.36) (see Figure). The responses to our highest isoproterenol
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dose were much larger than the responses reported in Lembo and 
colleagues’ study despite a higher isoproterenol dose in that 
study. These striking differences are not well explained.
In conclusion, we do not agree with the conclusions of Lembo and 
associates and suggest that the increased response to isoproterenol 
during insulin could be explained simply by a still-ongoing intrinsic 
vasodilator effect of insulin added to the response to isoproterenol. 
In fact, the same explanation could hold true for the diminished effect 
of sympathetic stimulation during insulin and BHT-933. As such, we 
believe there is currently not sufficient evidence for a specific mod­
ulator effect of insulin on /^-adrenergic vasodilator action.
Cees JJ. Tack, MD
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Drs Tack and Smits give a different interpretation of our results, 1 
mentioning a series of studies in which they assert that a vasodilator 
effect of insulin infused locally was reported. Actually, a careful pe­
rusal of these studies reveals that the citations were not entirely ap­
propriate. In particular, in the studies from Steinberg et al2 and Baron 
et al,3 insulin was administered systemically during a euglycemic 
clamp of long duration (about 3 hours) and not directly into the artery. 
The same systemic insulin infusion in euglycemic conditions was 
used in the Utriainen et al investigations.4 Furthermore, in the Creager 
et al study,5 insulin was infused locally in a dose range from 0.1 to 
1.0 mU/kg per minute, but the difference in FBF was observed only 
at the highest level of intrabrachial insulin infusion rate, which ob­
viously exposed the forearm to elevated pharmacological amounts of 
the hormone. High insulin levels (104 //U/mL) were reached in the 
Neahring et al study,6 which also claimed an insulin spillover into 
the systemic circulation, as demonstrated by the increase in plasma
insulin levels in the contralateral arm. Finally, Louard et al7 unequiv­
ocally demonstrated that insulin augments FBF (25%) only at a dose 
yielding deep venous insulin concentration of 125 pU/niL,1 about 
twofold higher than in our study.
In contrast, several studies7' 12 have clearly demonstrated that in­
sulin infusion directly into the brachial artery does not increase blood 
flow. In particular, at lower doses yielding deep venous insulin levels 
comparable to those reached in our study, no increase in FBF is 
observed when the infusion of the hormone is extended for longer 
periods.7,12 However, to satisfy the doubts of Tack and Smits, we 
have pooled our data and, confirming the results from the studies 
cited above, we were unable to see any impressive effect of insulin 
on FBF (3,02±0.2 versus 2.95±0.1 mL/min per 100 mL, n=24; NS). 
Thus, in this circumstance, their recommendation to express the 
results as a percentage of the baseline does not appear extremely 
appropriate.
Therefore, the authors must consider that their novel hypothesis, 
based on the fact that insulin directly infused into brachial artery 
evokes vasodilation, needs to be reexamined because such an insulin 
vasodilator effect is not uniformly observed.
Our conclusions regarding the cross talk between insulin and 
/3-adrenergic receptor signal transduction pathways at the vascular 
level were also attested to by a distinct series of studies in which we 
observed that propranolol, a selective /3-adrenergic-blocking agent, 
was able to partially restore the reflex sympathetic vascular response, 
counteracting the modulatory effect of insulin.1
However, supposing that insulin is concretely able to exert a non­
specific potentiating effect of the /?-adrenergic-evoked vasodilation 
through its independent vasodilator action, it is difficult for us to 
interpret the results obtained with sodium nitroprusside, in which, in 
contrast, insulin was unable to sensitize that response. Tack and Smits 
have their personal interpretation for this result also: They claim that 
we have not studied enough subjects. Thus, it is possible that in a 
larger group, the insulin-potentiating effect on sodium nitroprusside 
might be indubitably manifest. Probably they are not informed that 
Taddei et al13 have recently demonstrated that insulin, locally infused 
in a dose and time course similar to those used in our study, were 
unable to modify the response of sodium nitroprusside, entirely sup­
porting our findings and the conclusion that the insulin-potentiating 
effect on /3-adrenergic vasodilator pathways was not due to a non­
specific independent vasorelaxant action of the hormone. Further­
more, Tack and Smits also speculate that an intrinsic vasodilator ef­
fect of insulin may account for the diminished effect of sympathetic 
stimulation during insulin and BHT-933 infusion. However, even in 
this case, we cannot agree with their interpretation because in our 
previous studies14 using phenylephrine to evoke a distinct adreno- 
receptor-mediated vascular effect, we were unable to disclose an in­
sulin effect on phenylephrine-induced vasoconstriction, further 
sustaining the concept that the insulin effect on the vascular a 2- and 
^-adrenergic pathways must be considered specific. On this issue, 
we would like to quote recent basic studies in which has been 
clearly demonstrated the ability of insulin to increase /^-adrenergic 
responsiveness, 15 and the exact molecular mechanism has been pro­
posed also. 16
It remains to be explained why Tack and Smits have attained dif­
ferent results. Actually, this point is more difficult for us, since we 
did not have an opportunity to preview their manuscript before its 
publication. However, on the basis of their scant information, we can 
only speculate that prolonged infusion of insulin into the brachial 
artery may result in a spillover of the hormone into the systemic 
circulation, which may recruit a sympathomedullary mechanism. 17
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